<DOC>
	<DOCNO>NCT00744991</DOCNO>
	<brief_summary>The purpose study determine efficacy safety enzastaurin patient CTCL fail prior therapy .</brief_summary>
	<brief_title>A Study Patients With Relapsed Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Histologically confirm mycosis fungoides Sezary Syndrome Stage IB IVB disease screen Recurrent refractory disease least 1 prior systemic therapy Have adequate organ function define : At least 30 day must pass since treatment CTCL . Receiving concurrent treatment CTCL Unable swallow tablet Receiving high potency oral topical steroid . Low potency oral steroid may permit patient stable dose least 4 week prior screen . Oral topical antihistamine allow . Unable discontinue use carbamazepine , phenobarbital , phenytoin Have serious concomitant systemic disorder HIV Have serious cardiac condition myocardial infarction within past 6 month , angina , heart disease define New York Heart Association ( NYHA ) Class III IV Have ECG abnormality , Are pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>